MCID: BNG030
MIFTS: 51

Benign Ependymoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Benign Ependymoma

MalaCards integrated aliases for Benign Ependymoma:

Name: Benign Ependymoma 12 15
Ependymoma 44 71
Who Grade Ii Ependymal Tumor 12
Myxopapillary Ependymoma 71
Epithelial Ependymoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4844
MeSH 44 D004806
NCIt 50 C3017
SNOMED-CT 67 443643007
UMLS 71 C0014474 C0205769

Summaries for Benign Ependymoma

MalaCards based summary : Benign Ependymoma, also known as ependymoma, is related to anaplastic ependymoma and papillary ependymoma, and has symptoms including back pain An important gene associated with Benign Ependymoma is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are Signaling by GPCR and Gene Expression. The drugs Thiotepa and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and pineal, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Benign Ependymoma

Diseases in the Benign Ependymoma family:

Malignant Adult Ependymoma

Diseases related to Benign Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 472)
# Related Disease Score Top Affiliating Genes
1 anaplastic ependymoma 32.5 SYP PTEN NF2 GFAP
2 papillary ependymoma 32.2 SYP NF2 GFAP
3 clear cell ependymoma 32.1 ZFTA SYP NF2 GFAP
4 tanycytic ependymoma 32.0 ZFTA SYP NF2 GFAP
5 subependymoma 31.9 TSC2 SYP GFAP
6 high grade ependymoma 31.9 ZFTA NF2 KIAA1549 GFAP
7 medulloblastoma 31.0 TSC2 SYP PTEN MTOR GFAP AKT1
8 angiocentric glioma 30.6 SYP GFAP
9 malignant astrocytoma 30.6 PTEN KIAA1549 GFAP AKT1
10 cauda equina syndrome 30.5 SYP GFAP
11 neurilemmoma 30.4 NF2 GFAP AKT1
12 rhabdoid meningioma 30.3 SYP NF2 GFAP
13 obstructive hydrocephalus 30.3 TSC2 TSC1 SYP NF2 GFAP
14 pineocytoma 30.1 SYP GFAP
15 teratoma 30.1 SYP PTEN GFAP AKT1
16 chordoma 30.1 PTEN MTOR GFAP AKT1
17 pleomorphic xanthoastrocytoma 30.1 ZFTA SYP KIAA1549 GFAP
18 meningioma, familial 30.1 SYP PTEN NF2 KIAA1549 GFAP AKT1
19 ganglioglioma 30.0 TSC2 TSC1 SYP GFAP
20 cellular ependymoma 29.9 ZFTA SYP NF2 GFAP
21 myxopapillary ependymoma 29.9 ZFTA SYP NF2 GFAP
22 cystic teratoma 29.9 SYP PTEN GFAP
23 neurofibroma 29.9 SYP PTEN NF2
24 ganglioneuroma 29.9 SYP PTEN GFAP
25 pilocytic astrocytoma 29.9 SYP PTEN MTOR KIAA1549 GFAP AKT1
26 gliofibroma 29.9 SYP KIAA1549 GFAP
27 choroid plexus cancer 29.9 ZFTA SYP GFAP
28 atypical teratoid rhabdoid tumor 29.8 ZFTA SYP NF2 GFAP
29 glioblastoma 29.8 RPS6KB1 PTEN MTOR MIR323A GFAP AKT1
30 diffuse astrocytoma 29.8 KIAA1549 GFAP AKT1
31 chordoid meningioma 29.8 SYP NF2 GFAP
32 pilomyxoid astrocytoma 29.8 SYP KIAA1549 GFAP
33 clear cell meningioma 29.8 SYP NF2 GFAP
34 gangliocytoma 29.8 SYP PTEN KIAA1549 GFAP
35 gliosarcoma 29.7 SYP PTEN MTOR GFAP AKT1
36 giant cell glioblastoma 29.6 SYP PTEN MTOR GFAP
37 meningioma, radiation-induced 29.5 NF2 AKT1
38 subependymal giant cell astrocytoma 29.5 TSC2 TSC1 SYP RHEB MTOR MIR323A
39 spinal cancer 29.4 ZFTA SYP NF2 KIAA1549 GFAP
40 brain cancer 29.4 SYP PTEN NF2 GFAP AKT1
41 spinal cord disease 29.2 TSC2 TSC1 SYP RHEB NF2 MTOR
42 renal cell carcinoma, nonpapillary 29.1 TSC2 TSC1 RHEB PTEN MTOR EIF4EBP1
43 central nervous system cancer 28.8 SYP PTEN NF2 KIAA1549 GFAP AKT1
44 subependymal glioma 28.6 TSC2 TSC1 TBC1D7 RPTOR RPS6KB1 RICTOR
45 cowden syndrome 27.5 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
46 tuberous sclerosis 27.4 TSC2 TSC1 TBC1D7 SYP RPTOR RPS6KB1
47 tuberous sclerosis 1 27.3 TSC2 TSC1 TBC1D7 RPTOR RPS6KB1 RICTOR
48 pediatric ependymoma 11.4
49 pediatric supratentorial ependymoma 11.3
50 spinal cord ependymoma 11.3

Graphical network of the top 20 diseases related to Benign Ependymoma:



Diseases related to Benign Ependymoma

Symptoms & Phenotypes for Benign Ependymoma

UMLS symptoms related to Benign Ependymoma:


back pain

GenomeRNAi Phenotypes related to Benign Ependymoma according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.27 MTOR RHEB
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.27 TSC1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 10.27 PTEN
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.27 AKT1 MTOR RHEB
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 10.27 RICTOR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.27 MTOR RHEB
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.27 AKT1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 10.27 TSC1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 10.27 TSC1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.27 RHEB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.27 TSC1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.27 AKT1 MTOR RHEB RICTOR
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.27 AKT1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.27 MTOR
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 10.27 RHEB
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.27 RHEB
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.27 MTOR
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.27 AKT1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-82 10.27 TSC1
20 Decreased viability GR00055-A-1 9.93 MTOR
21 Decreased viability GR00055-A-2 9.93 MTOR
22 Decreased viability GR00221-A-1 9.93 AKT1 MLST8 MTOR RHEB RPS6KB1
23 Decreased viability GR00221-A-2 9.93 AKT1
24 Decreased viability GR00221-A-3 9.93 AKT1
25 Decreased viability GR00221-A-4 9.93 AKT1 MLST8 MTOR
26 Decreased viability GR00249-S 9.93 AKT1
27 Decreased viability GR00301-A 9.93 RPS6KB1
28 Decreased viability GR00342-S-1 9.93 MTOR
29 Decreased viability GR00342-S-2 9.93 MTOR
30 Decreased viability GR00381-A-1 9.93 RPS6KB1
31 Decreased viability GR00386-A-1 9.93 RHEB
32 Decreased viability GR00402-S-2 9.93 RPS6KB1
33 Decreased cell migration GR00055-A-1 9.73 AKT1 NF2 RICTOR TSC1
34 Decreased cell migration GR00055-A-3 9.73 MTOR RICTOR
35 Decreased viability with paclitaxel GR00179-A-1 9.02 MTOR RPS6KB1
36 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
37 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR RPS6KB1

MGI Mouse Phenotypes related to Benign Ependymoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 AKT1 EIF4EBP1 EPRS1 FKBP1A GFAP MTOR
2 growth/size/body region MP:0005378 10.28 AKT1 EIF4EBP1 EPRS1 FKBP1A GFAP MLST8
3 cardiovascular system MP:0005385 10.27 AKT1 EIF4EBP1 FKBP1A GFAP MLST8 MTOR
4 embryo MP:0005380 10.27 AKT1 EPRS1 FKBP1A MLST8 MTOR NF2
5 homeostasis/metabolism MP:0005376 10.24 AKT1 EIF4EBP1 EPRS1 FKBP1A GFAP KIAA1549
6 adipose tissue MP:0005375 10.16 AKT1 EIF4EBP1 EPRS1 KIAA1549 MTOR PTEN
7 endocrine/exocrine gland MP:0005379 10.13 AKT1 MTOR NF2 PTEN RHEB RICTOR
8 mortality/aging MP:0010768 10.13 AKT1 EIF4EBP1 EPRS1 FKBP1A GFAP MLST8
9 liver/biliary system MP:0005370 9.92 AKT1 FKBP1A NF2 PTEN RICTOR RPTOR
10 muscle MP:0005369 9.9 AKT1 EIF4EBP1 FKBP1A GFAP MTOR PTEN
11 neoplasm MP:0002006 9.5 AKT1 NF2 PTEN RICTOR RPS6KB1 TSC1
12 normal MP:0002873 9.28 AKT1 EPRS1 FKBP1A GFAP MTOR PTEN

Drugs & Therapeutics for Benign Ependymoma

Drugs for Benign Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
2
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
3
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6 Trofosfamide Investigational Phase 2, Phase 3 22089-22-1
7 Etoposide phosphate Phase 2, Phase 3
8 Psychotropic Drugs Phase 2, Phase 3
9 Anticonvulsants Phase 2, Phase 3
10
Mesna Approved, Investigational Phase 2 3375-50-6 598
11
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
12
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
13
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
14
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
15
Ivosidenib Approved, Investigational Phase 2 1448347-49-6 71657455
16 Fenofibric acid Approved Phase 2 42017-89-0
17
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
18
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
19
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
20
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
21
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
22
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
23
Olaparib Approved Phase 2 763113-22-0 23725625
24
Memantine Approved, Investigational Phase 2 19982-08-2 4054
25
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
26
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
27
Vinblastine Approved Phase 2 865-21-4 13342 241903
28
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
29
nivolumab Approved Phase 1, Phase 2 946414-94-4
30
Iodine Approved, Investigational Phase 2 7553-56-2 807
31
carbamide peroxide Approved Phase 2 124-43-6
32
Bevacizumab Approved, Investigational Phase 2 216974-75-3
33
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
34
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
35
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
36
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
37
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
38
Lopinavir Approved Phase 2 192725-17-0 92727
39
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
40
Methionine Approved, Nutraceutical Phase 2 63-68-3 6137
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
42 Ensartinib Investigational Phase 2 1370651-20-9
43
tipifarnib Investigational Phase 2 192185-72-1 159324
44
Camptothecin Experimental Phase 2 7689-03-4
45
Cadexomer iodine Experimental Phase 2 94820-09-4
46
Imetelstat Investigational Phase 2 868169-64-6
47 acivicin Phase 2
48 Immunoglobulins, Intravenous Phase 2
49 Immunoglobulin G Phase 2
50 Deoxyglucose Phase 2

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
2 Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents Completed NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
3 An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
4 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years Active, not recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine
5 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
6 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
7 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
8 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
9 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma Completed NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
10 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
11 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
12 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
13 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
14 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
15 A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
16 A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
17 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
18 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
19 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
20 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
21 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
22 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
23 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
24 A Phase II Study of Pemetrexed in Children With Recurrent Malignancies Completed NCT00520936 Phase 2 pemetrexed
25 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
26 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib
27 Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG Recruiting NCT04049669 Phase 2 Indoximod;Indoximod;Temozolomide;Cyclophosphamide;Etoposide;Lomustine
28 A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
29 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
30 Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Recruiting NCT03727841 Phase 2 Marizomib
31 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Recruiting NCT04195555 Phase 2 Ivosidenib
32 A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma and ATRT Recruiting NCT01356290 Phase 2 Bevacizumab;Thalidomide;Celecoxib;Fenofibric acid;Etoposide;Cyclophosphamide;Etoposide phosphate;Cytarabine
33 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations Recruiting NCT04320888 Phase 2 Selpercatinib
34 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Recruiting NCT03526250 Phase 2 Palbociclib
35 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
36 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations Recruiting NCT03210714 Phase 2 Erdafitinib
37 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
38 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
39 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
40 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations Recruiting NCT03213652 Phase 2 Ensartinib
41 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study Recruiting NCT03194906 Phase 2 Memantine
42 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
43 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
44 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
45 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Recruiting NCT03698994 Phase 2 Ulixertinib
46 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Recruiting NCT04284774 Phase 2 Tipifarnib
47 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
48 A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects Active, not recruiting NCT00187226 Phase 2
49 A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma Active, not recruiting NCT02125786 Phase 2 ^1^8F-Fluorodeoxyglucose;^1^1C-methionine
50 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Active, not recruiting NCT02155920 Phase 2 Everolimus

Search NIH Clinical Center for Benign Ependymoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Carmustine

Cochrane evidence based reviews: ependymoma

Genetic Tests for Benign Ependymoma

Anatomical Context for Benign Ependymoma

MalaCards organs/tissues related to Benign Ependymoma:

40
Spinal Cord, Brain, Pineal, Pituitary, Endothelial, Medulla Oblongata, Ovary

Publications for Benign Ependymoma

Articles related to Benign Ependymoma:

(show top 50) (show all 3864)
# Title Authors PMID Year
1
YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas. 61
33074854 2021
2
Supratentorial ependymoma in childhood: more than just RELA or YAP. 61
33481105 2021
3
Outcomes following limited-volume proton therapy for multifocal spinal myxopapillary ependymoma. 61
33226179 2021
4
Recurring pediatric anaplastic ependymoma with rare peritoneal carcinomatosis: a case report and hypothesis of mechanism. 61
32681369 2021
5
Differentiation Between Ependymoma and Medulloblastoma in Children with Radiomics Approach. 61
32222329 2021
6
The Impact of Socioeconomic Status (SES) on Cognitive Outcomes Following Radiotherapy for Pediatric Brain Tumors: A Prospective, Longitudinal Trial. 61
33543269 2021
7
Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. 61
33536079 2021
8
Pigmented Ependymoma of the Fourth Ventricle-A Curious Entity: Report of a Rare Case With Review of Literature. 61
32450730 2021
9
Bioinformatics analysis of microarray data reveals epithelial-mesenchymal-transition in pediatric ependymoma. 61
33595943 2021
10
Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma. 61
33576087 2021
11
Extra-axial sacral soft tissue giant cell ependymoma affecting a child: Case report and review of the literature. 61
33569822 2021
12
Outcomes after first relapse of childhood intracranial ependymoma. 61
33565268 2021
13
Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. 61
33580238 2021
14
Measurement of Apparent Diffusion Coefficient (ADC) Values of Ependymoma and Medulloblastoma Tumors: a Patient-based Study. 61
33564638 2021
15
Benefit of Static FET PET in Pretreated Pediatric Brain Tumor Patients with Equivocal Conventional MRI Results. 61
33598897 2021
16
Advances in the classification and treatment of pediatric brain tumors. 61
33278109 2021
17
Intraoperative Consultation in the Diagnosis of Posterior fossa Brain Tumors following the 2016 WHO update. 61
33606311 2021
18
[Spinal tumors]. 61
33570679 2021
19
Medulloblastoma: Clinical presentation. 61
31494131 2021
20
Analysis of the P53N a Novel Protein Encoded on Chromosome 22q12.1-12.3 in Glioblastomas and Ependymomas Specimens. 61
33595778 2021
21
Intracranial ependymomas: The role of advanced neuroimaging in diagnosis and management. 61
33525963 2021
22
Two cases of normal pressure hydrocephalus caused by ependymoma of the cauda equina. 61
33500823 2021
23
Spinal Ependymoma Identified Following Spinal Anesthesia for Cesarean Delivery. 61
33564549 2021
24
Spinal schwannoma causes acute subarachnoid haemorrhage: A case report and literature review. 61
33450272 2021
25
[Ependymoma of the Sella Turcica and Suprasellar Region]. 61
33494065 2021
26
Proton Therapy for Pediatric Ependymoma: Mature Results from a Bicentric Study. 61
33508372 2021
27
Spatial Agreement of Brainstem Dose Distributions Depending on Biological Model in Proton Therapy for Pediatric Brain Tumors. 61
33490724 2021
28
Preoperative Intracranial Dissemination of Spinal Myxopapillary Ependymoma Attributed to Tumor Hemorrhage. 61
32889190 2021
29
Clinical Image of a Spinal Ependymoma Discovered 8 Years after Initial Misdiagnosis as an Idiopathic Syringomyelia. 61
33022432 2021
30
Ependymoma of the broad ligament mimicking an ovarian surface epithelial tumor. 61
33294091 2021
31
Intra-Axial Frontal Cyst with Ependymoma-Like Proliferation: Neuroectodermal or Neurenteric? 61
33068007 2021
32
MRI appearance of anaplastic extraventricular ependymoma. 61
33423219 2021
33
Ependymoma relapse goes along with a relatively stable epigenome, but a severely altered tumor morphology. 61
32633004 2021
34
Ependymoma with C11orf95-MAML2 fusion: presenting with granular cell and ganglion cell features. 61
33221956 2021
35
CSF Otorrhea: A Rare Presentation of Spinal Myxopapillary Ependymoma. 61
33485885 2021
36
Grade III intradural extramedullary anaplastic ependymoma managed with near-complete resection and adjuvant radiotherapy: a case report. 61
33468988 2021
37
Supratentorial ependymoma with YAP1:FAM118B fusion: A case report. 61
33480048 2021
38
The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study. 61
33387039 2021
39
Solid-cystic cortical ependymoma: a diagnostic dilemma. 61
33404714 2021
40
Giant intradural myxopapillary ependymoma: review of literature. 61
33509888 2021
41
Clinical outcomes in a large pediatric cohort of patients with ependymoma treated with proton radiotherapy. 61
32514542 2021
42
The potentially therapeutic targets of pediatric anaplastic ependymoma by transcriptome profiling. 61
32940047 2021
43
Intracytoplasmic dot-like inclusions as cytopathologically useful findings of ependymoma: Case report of adolescent supratentorial anaplastic ependymoma with clear cell morphology. 61
33505691 2021
44
Clinical features, treatments, and prognostic factors of spinal myxopapillary ependymoma. 61
33412325 2021
45
A Paravermal Trans-Cerebellar Approach to the Posterior Fossa Tumor Causes Hypertrophic Olivary Degeneration by Dentate Nucleus Injury. 61
33445527 2021
46
Abnormal spindle-like microcephaly-associated (ASPM) gene expression in posterior fossa brain tumors of childhood and adolescence. 61
32591873 2021
47
MR imaging findings in primary spinal cord glioblastoma. 61
33193932 2021
48
Neurofibromatosis 2: rare constellation of findings with extensive cranial nerve involvement. 61
33240459 2021
49
mRNA and miRNA Expression Analyses of the MYC/E2F/miR-17-92 Network in the Most Common Pediatric Brain Tumors. 61
33430425 2021
50
Ovarian tissue cryopreservation and transplantation in patients with central nervous system tumours. 61
33394011 2021

Variations for Benign Ependymoma

Expression for Benign Ependymoma

Search GEO for disease gene expression data for Benign Ependymoma.

Pathways for Benign Ependymoma

Pathways related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.24 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
2
Show member pathways
13.87 TSC2 TSC1 RPTOR RICTOR RHEB PTEN
3
Show member pathways
13.44 TSC2 TSC1 RPS6KB1 PTEN MTOR EIF4EBP1
4
Show member pathways
13.36 TSC2 TSC1 RPTOR RPS6KB1 RHEB MTOR
5
Show member pathways
13.17 TSC2 TSC1 RPTOR RHEB MTOR MLST8
6
Show member pathways
13.16 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
7
Show member pathways
13.15 TSC2 RICTOR PTEN MTOR MLST8 AKT1
8
Show member pathways
13.12 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
9
Show member pathways
13.1 TSC2 RPS6KB1 RHEB PTEN MTOR AKT1
10
Show member pathways
13.1 TSC2 TSC1 RPTOR RICTOR RHEB PTEN
11
Show member pathways
13.03 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
12
Show member pathways
13.02 TSC2 TSC1 RPS6KB1 RHEB MTOR EIF4EBP1
13
Show member pathways
12.97 TSC2 RPS6KB1 RHEB PTEN MTOR EIF4EBP1
14 12.88 TSC2 TSC1 RHEB MTOR EIF4EBP1 AKT1
15
Show member pathways
12.81 TSC2 RICTOR PTEN MTOR MLST8 AKT1
16
Show member pathways
12.8 RPTOR PTEN MTOR MLST8 EIF4EBP1 AKT1
17
Show member pathways
12.77 TSC2 TSC1 RPS6KB1 PTEN MTOR AKT1
18
Show member pathways
12.7 TSC2 RPS6KB1 RHEB MTOR AKT1
19
Show member pathways
12.68 RPS6KB1 PTEN MTOR EIF4EBP1 AKT1
20
Show member pathways
12.65 TSC2 TSC1 RPTOR RPS6KB1 RHEB MTOR
21
Show member pathways
12.56 RPS6KB1 PTEN MTOR EIF4EBP1 AKT1
22
Show member pathways
12.56 TSC2 TSC1 RPS6KB1 RHEB MTOR EIF4EBP1
23
Show member pathways
12.55 TSC2 TSC1 RPS6KB1 RHEB PTEN MTOR
24
Show member pathways
12.54 RPTOR RPS6KB1 PTEN MTOR AKT1
25
Show member pathways
12.54 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
26
Show member pathways
12.45 TSC2 RPS6KB1 PTEN MTOR EIF4EBP1 AKT1
27 12.44 RPTOR RPS6KB1 MTOR AKT1
28 12.4 TSC2 TSC1 RPTOR RPS6KB1 RICTOR MTOR
29
Show member pathways
12.38 RPS6KB1 MTOR EIF4EBP1 AKT1
30
Show member pathways
12.38 TSC2 TSC1 RPTOR RPS6KB1 MTOR EIF4EBP1
31 12.34 RPS6KB1 RICTOR PTEN MTOR EIF4EBP1 AKT1
32 12.31 TSC2 TSC1 RHEB PTEN MTOR AKT1
33 12.31 TSC2 TSC1 RHEB PTEN MTOR EIF4EBP1
34
Show member pathways
12.29 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
35
Show member pathways
12.28 TSC2 TSC1 RPTOR RPS6KB1 RHEB MTOR
36
Show member pathways
12.27 RICTOR MTOR MLST8 AKT1
37 12.23 TSC2 RPS6KB1 MTOR EIF4EBP1 AKT1
38 12.22 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
39
Show member pathways
12.15 TSC2 RPS6KB1 RHEB MTOR EIF4EBP1
40
Show member pathways
12.14 RPS6KB1 MTOR EIF4EBP1 AKT1
41 12.14 TSC2 TSC1 RPS6KB1 PTEN NF2 MTOR
42 12.1 TSC2 RHEB MTOR AKT1
43
Show member pathways
12.09 TSC2 TSC1 RPTOR RPS6KB1 RICTOR RHEB
44
Show member pathways
12.08 TSC2 TSC1 RPTOR RHEB MTOR MLST8
45
Show member pathways
12.05 RPS6KB1 PTEN MTOR AKT1
46 12.05 TSC2 TSC1 TBC1D7 RHEB PTEN AKT1
47 12.04 RPS6KB1 MTOR EIF4EBP1 AKT1
48 12.01 RICTOR MTOR MLST8 AKT1
49 11.99 TSC2 TSC1 RPTOR RHEB PTEN MTOR
50
Show member pathways
11.98 TSC2 RICTOR MTOR MLST8 AKT1

GO Terms for Benign Ependymoma

Cellular components related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.21 TSC2 TSC1 RPTOR RPS6KB1 RHEB PTEN
2 cytosol GO:0005829 9.53 TSC2 TSC1 TBC1D7 RPTOR RPS6KB1 RICTOR
3 postsynaptic cytosol GO:0099524 9.43 PTEN MTOR EIF4EBP1
4 TORC2 complex GO:0031932 9.33 RICTOR MTOR MLST8
5 TSC1-TSC2 complex GO:0033596 9.32 TSC2 TSC1
6 TORC1 complex GO:0031931 9.13 RPTOR MTOR MLST8

Biological processes related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 peptidyl-serine phosphorylation GO:0018105 9.9 RPS6KB1 RICTOR MTOR AKT1
2 regulation of cell cycle GO:0051726 9.89 TSC2 TSC1 PTEN NF2
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 RICTOR MTOR MLST8
4 cell cycle arrest GO:0007050 9.86 RPTOR RHEB MTOR MLST8
5 regulation of GTPase activity GO:0043087 9.85 RICTOR MTOR MLST8
6 negative regulation of protein kinase activity GO:0006469 9.85 TSC2 NF2 AKT1
7 response to organic substance GO:0010033 9.85 RPS6KB1 PTEN AKT1
8 cellular response to hypoxia GO:0071456 9.85 PTEN MTOR EIF4EBP1 AKT1
9 negative regulation of translation GO:0017148 9.84 TSC1 EPRS1 EIF4EBP1
10 response to nutrient GO:0007584 9.83 RPS6KB1 PTEN MTOR
11 response to insulin GO:0032868 9.83 TSC1 RPS6KB1 MTOR
12 response to nutrient levels GO:0031667 9.83 TSC1 RPS6KB1 MTOR
13 cellular response to insulin stimulus GO:0032869 9.83 RPS6KB1 PTEN EPRS1 AKT1
14 regulation of translation GO:0006417 9.83 TSC1 RPS6KB1 EPRS1 EIF4EBP1 AKT1
15 regulation of cellular response to heat GO:1900034 9.82 RPTOR MTOR MLST8
16 regulation of actin cytoskeleton organization GO:0032956 9.81 RICTOR MTOR MLST8
17 negative regulation of neuron projection development GO:0010977 9.81 TSC1 PTEN GFAP
18 negative regulation of protein kinase B signaling GO:0051898 9.8 TSC2 PTEN AKT1
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 RPS6KB1 MTOR AKT1
20 regulation of macroautophagy GO:0016241 9.8 RPTOR RHEB MTOR MLST8
21 positive regulation of stress fiber assembly GO:0051496 9.79 TSC1 NF2 MTOR
22 positive regulation of protein serine/threonine kinase activity GO:0071902 9.79 RPTOR RICTOR MLST8
23 positive regulation of actin filament polymerization GO:0030838 9.78 RICTOR MTOR MLST8
24 positive regulation of endothelial cell proliferation GO:0001938 9.78 RPTOR RICTOR MTOR AKT1
25 negative regulation of insulin receptor signaling pathway GO:0046627 9.75 TSC2 TSC1 RPS6KB1
26 germ cell development GO:0007281 9.74 RPS6KB1 MTOR AKT1
27 negative regulation of TOR signaling GO:0032007 9.71 TSC2 TSC1 TBC1D7
28 insulin-like growth factor receptor signaling pathway GO:0048009 9.69 TSC2 AKT1
29 regulation of protein kinase B signaling GO:0051896 9.69 RICTOR PTEN MTOR
30 cellular response to nutrient levels GO:0031669 9.68 RPTOR MTOR
31 regulation of glycogen biosynthetic process GO:0005979 9.67 MTOR AKT1
32 positive regulation of transcription by RNA polymerase III GO:0045945 9.66 RPTOR MTOR
33 cellular response to leucine GO:0071233 9.65 RPTOR MTOR
34 negative regulation of macroautophagy GO:0016242 9.63 TSC1 MTOR AKT1
35 protein kinase B signaling GO:0043491 9.62 TSC2 RPS6KB1 PTEN AKT1
36 cellular response to decreased oxygen levels GO:0036294 9.58 PTEN AKT1
37 anoikis GO:0043276 9.58 TSC2 MTOR AKT1
38 positive regulation of TOR signaling GO:0032008 9.56 RPTOR RICTOR RHEB MLST8
39 TORC1 signaling GO:0038202 9.54 RPTOR MTOR MLST8
40 activation of protein kinase B activity GO:0032148 9.46 RICTOR MTOR MLST8 AKT1
41 negative regulation of cell size GO:0045792 9.26 TSC1 PTEN MTOR AKT1
42 TOR signaling GO:0031929 9.17 RPTOR RPS6KB1 RICTOR MTOR MLST8 EIF4EBP1

Molecular functions related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTPase activating protein binding GO:0032794 9.4 TSC1 AKT1
2 RNA polymerase III type 3 promoter sequence-specific DNA binding GO:0001006 9.37 RPTOR MTOR
3 TFIIIC-class transcription factor complex binding GO:0001156 9.32 RPTOR MTOR
4 RNA polymerase III type 2 promoter sequence-specific DNA binding GO:0001003 9.26 RPTOR MTOR
5 RNA polymerase III type 1 promoter sequence-specific DNA binding GO:0001002 9.16 RPTOR MTOR
6 protein phosphatase 2A binding GO:0051721 9.13 RPS6KB1 EIF4EBP1 AKT1
7 protein kinase binding GO:0019901 9.1 RPTOR RICTOR RHEB PTEN MTOR AKT1

Sources for Benign Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....